![Linifanib (ABT-869) - CAS# 796967-16-3 acin(DU 6859A) [3] Combining Tipifarnib with 10](https://cdn.shopify.com/s/files/1/0389/1897/9723/products/M7838_1619054324.gif?v=1742686204)
Pay in 4 interest-free payments of $27.00 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
[3] Combining Tipifarnib with 10 nM 4-OH-tamoxifen in the presence of E2 reduces the IC50 8-fold from 400 to 50 nM
Flow cytometry is also performed to determine the expression marker Ki-67 in U2OS following 48 h treatment with DMSO or 10 uM JW74
26(2):278-288
InChiKey: MQMKRQLTIWPEDM-UHFFFAOYSA-N
2) as a CYP17 lyase inhibitor and 3) by decreasing overall androgen receptor levels in prostate cancer tumors
Linifanib (ABT-869) - CAS# 796967-16-3 acin(DU 6859A) [3] Combining Tipifarnib with 10Linifanib, CAS No. 796967 16 3, also known as ABT 869, is an orally bioavailable, small molecule receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. Linifanib inhibits members of the vascular endothelial growth factor (VEGF) and platelet derived growth factor (PDGF) receptor families; it exhibits much less activity against unrelated RTKs, soluble tyrosine kinases, or serine threonine kinases. This agent does not have a